-
8m 4sPart 3 | Session 1 EAS 2026 Data Highlights: Emerging Evidence on Targeted Therapies
-
4m 42sPart 3 | Session 2 EAS 2026 Data Highlights: Lp(a) and Residual Risk: Entering the HORIZON Era
-
3m 47sPart 3 | Session 3 EAS 2026 Data Highlights: A Look at Interim Results from the Heart-2 Study
-
2m 51s
-
12m 11s
-
13m 49s
-
5m 53s
The burden of hypertriglyceridemia (HTG) spans a broad and diverse patient population, from rare genetic disorders such as familial chylomicronaemia syndrome (FCS) to mixed hyperlipidaemia and familial dyslipidaemias. Current treatment strategies, including statins and fibrates, remain limited in their ability to adequately control triglyceride levels in many patients, highlighting the need for education around emerging therapeutic classes. ApoC-III–targeted therapies are demonstrating significant TG-lowering potential and are increasingly being evaluated across a wider range of patient populations, including those with FCS.
In this video, Dr Michos (Johns Hopkins University School of Medicine, Baltimore, US) is joined by Dr Christie Ballantyne (Baylor College of Medicine, Houston, US) for an in-depth discussion on real-world implications and clinical decision-making around applying emerging guidance and evidence in severe hypertriglyceridemia and FCS. They review evolving guidelines and what emerging data tells us about managing complex patient populations.
This session is supported by an unrestricted educational grant from Arrowhead Pharmaceuticals.
This programme provides a focused spotlight on the latest developments and data presented at the European Atherosclerosis Society (EAS) Congress. Through a series of sessions, recorded at EAS and contributed by various faculty members, each offers concise analysis of late-breaking trial data, sub-analyses, and the clinical implications shaping contemporary lipid management.
Key Learning Objectives
- Identify suitable patients for ApoC-III initiation using validated scoring parameters
- Recall the most recent guidance for the use of ApoC-III inhibitor therapy
- Discuss emerging clinical evidence of TG-lowering therapies across important trial sub-populations
Target Audience
- Cardiologists
- Lipidologists
- Gastroenterologists
- Endocrinologists
- Other specialists associated with the management of familial chylomicronaemia syndrome (FCS)
More from this programme
Part 1
A Deep Dive Into the Data: Targeting ApoC-III Special Populations
The burden of hypertriglyceridemia (HTG) spans a broad and diverse patient population, from rare genetic disorders such as familial chylomicronaemia syndrome (FCS) to mixed hyperlipidaemia and familial dyslipidaemias. Current treatment strategies, including statins and fibrates, remain limited in their ability to adequately control triglyceride levels in many patients, highlighting the need for education around emerging therapeutic classes. ApoC-III–targeted therapies are demonstrating significant TG-lowering potential and are increasingly being evaluated across a wider range of patient populations, including those with FCS.
In this video, Dr Erin Michos (Johns Hopkins University School of Medicine, Baltimore, US) provides a deep dive into data presented at EAS 2026, targeting APOC-III in special populations.
This session is supported by an unrestricted educational grant from Arrowhead Pharmaceuticals.
Part 2
In Context: A Peer-To-Peer Discussion on ApoC-III in Special Populations and Other Emerging Data
The burden of hypertriglyceridemia (HTG) spans a broad and diverse patient population, from rare genetic disorders such as familial chylomicronaemia syndrome (FCS) to mixed hyperlipidaemia and familial dyslipidaemias. Current treatment strategies, including statins and fibrates, remain limited in their ability to adequately control triglyceride levels in many patients, highlighting the need for education around emerging therapeutic classes. ApoC-III–targeted therapies are demonstrating significant TG-lowering potential and are increasingly being evaluated across a wider range of patient populations, including those with FCS.
In this video, Dr Michos (Johns Hopkins University School of Medicine, Baltimore, US) is joined by Dr Christie Ballantyne (Baylor College of Medicine, Houston, US) for an in-depth discussion on real-world implications and clinical decision-making around applying emerging guidance and evidence in severe hypertriglyceridemia and FCS. They review evolving guidelines and what emerging data tells us about managing complex patient populations.
This session is supported by an unrestricted educational grant from Arrowhead Pharmaceuticals.
Part 3
EAS 2026 Data Highlights
Expert analysis of breaking congress data, highlighting key takeaways and impact on clinical practice.
Faculty Biographies
Erin D Michos
Associate Professor of Medicine and Director of Women's Cardiovascular Health
Dr Erin Michos is an Associate Professor of Medicine in the Division of Cardiology at the Johns Hopkins University School of Medicine, with joint appointment in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. She is the Director of Women’s Cardiovascular Heath and Associate Director of Preventive Cardiology with the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
Dr Michos is an internationally known expert in Preventive Cardiology and Women’s Health and has authored over 350 publications. Her research has focused on cardiovascular disease among women; coronary artery calcium, inflammatory markers, and other novel biomarkers of cardiovascular risk; lipids; and vitamin D and other supplements. She is an Associate Editor for Circulation and the American Journal of Preventive Cardiology.
Following receipt of her medical degree from Northwestern University, Dr. Michos…
Christie Ballantyne
Chief of Cardiovascular Research and Director of the Center for Cardiometabolic Disease Prevention
Dr Christie Ballantyne is the Chief of Cardiovascular Research, Director of the Center for Cardiometabolic Disease Prevention, and Professor of Medicine at Baylor College of Medicine in Texas, US.
He received his MD from Baylor College of Medicine and performed both his internal medicine residency at The University of Texas Southwestern Medical School. He completed a cardiology fellowship at Baylor College of Medicine and an American Heart Association/Bugher Foundation Fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor.
Dr Ballantyne is an internationally-renowned expert on lipids, atherosclerosis and heart disease prevention. His research interest in the prevention of heart disease has led him to become an established investigator for the American Heart Association and to receive continuous funding from the NIH since joining the faculty in 1988 in basic research of leukocyte- endothelial interactions,…